RxDoctor Payments DataLook up a doctor →

Lori Payne, NP

Dermatology · Abbeville, SCNPI 1205281011

Payments from drug & device makers

$20,710in general payments, 2019–2025

Across 879 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$3K
  • Sun Pharmaceutical Industries Inc.$2K
  • Pfizer$2K
  • Lilly USA, LLC$2K
  • UCB, Inc.$1K
  • plus $9K from 22 others

What the payments were for

  • Speaking & faculty fees$1231%
  • Food & beverage$19,68295%
  • Education$9064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,710 in reported general payments places this provider in the 85th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$64,701
Medicare patients
453
Services billed
1,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab58$240,485
Taltz AutoinjectorIxekizumab30$198,516
Humira(Cf) PenAdalimumab12$191,190
TremfyaGuselkumab13$174,132
OtezlaApremilast26$123,103
RinvoqUpadacitinib11$72,866
Clobetasol Propionate253$10,153
Doxycycline Monohydrate229$5,106
Ketoconazole167$2,912
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc226$2,843
Metronidazole45$2,779
Ammonium Lactate111$2,503
Fluorouracil37$2,300
Triamcinolone Acetonide119$1,963
Mupirocin291$1,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,753$174,13213 claims
AmgenOtezla$728$123,10326 claims
AbbVieRinvoq$3,293$72,86611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Abbeville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →